Auto-antibodies in autoimmune hepatitis: Anti-soluble liver antigen (SLA)

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 3, 2012, Pages 244-246

  Johanet, Catherine ^a   Ballot, Eric ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; SOLUBLE LIVER ANTIGEN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE HEPATITIS; HUMAN; PATHOGENESIS; PROGNOSIS; TREATMENT RESPONSE;

AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; HEPATITIS, AUTOIMMUNE; HLA-DR3 ANTIGEN; HUMANS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK ASSESSMENT;

EID: 84861724497     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.10.013     Document Type: Article

References (25)

1. Manns M., Gerken G., Kyriatsoulis A., Staritz M., Meyer Zum Büschenfelde K.H. Characterization of a new subgroup of autoimmune chronic active hepatitis by auto-antibodies against a soluble liver antigen. Lancet 1987, 1:292-294.
2. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
3. Hennes E.M., Zeniya M., Czaja A.J., Parés A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
4. Wies I., Brunner S., Henninge J., Herkel J., Kanzler S., Meyer Zum Büschenfelde K.H., et al. Identification of target antigen for SLA/LP auto-antibodies in autoimmune hepatitis. Lancet 2000, 355:1510-1515.
5. Costa M., Rodriguez-Sanchez J.L., Czaja A.J., et al. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(ser)sec complex recognized by auto-antibodies from patients with type 1 autoimmune hepatitis. Clin Exp Immunol 2000, 121:364-374.
6. Volkmann M., Martin L., Bäurle A., Heid H., Strassburg C.P., Trautwein C., et al. Soluble liver antigen: isolation of a 35-kD recombinant protein (SLA-p-35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001, 33:591-596.
7. Araiso Y., Palioura S., Ishitani R., Sherrer R.L., O'Donoghue P., Yuan J., et al. Structural insights into RNA-dependent eukaryal and archaeal selenocysteine formation. Nucleic Acids Res 2008, 36:1187-1199.
8. Volkmann M., Luithle D., Zentgraf H., Schnölzer M., Fiedler S., Heid H., et al. SLA/Lp/tRNP(ser)sec antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun 2010, 34:59-65.
9. Czaja A.J., Carpentier H.A., Manns M.P. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993, 105:1522-1528.
10. Lohse A.W., Gerken G., Mohr H., Löhr H.F., Treichel U., Dienes H.P., et al. Relation between autoimmune liver disease and viral hepatitis: clinical and serological characteristics in 859 patients. J Gastroenterol 1995, 33:527-533.
11. Kanzler S., Weidemann C., Gerken G., Löhr H.F., Galle P.R., Meyer zum Büschenfelde K.H., et al. Clinical significance of auto-antibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999, 31:635-640.
12. Nishioka M., Morshed S.A., Parveen S., Kono K., Matsuoka H., Manns M.P. Antibodies to P450IID6, SLA, PDH-E2 and BCKD-E2 in Japanese patients with chronic hepatitis. J Gastroenterol Hepatol 1997, 12:862-868.
13. Miyakawa H., Kawashima Y., Kitazawa E., Kawaguchi N., Kato T., Kikuchi K., et al. Low frequency of anti-SLA/LP auto-antibodies in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun 2003, 21:77-82.
14. Ma Y., Okamoto M., Thomas M.G., Bogdanos D.P., Lopes A.R., Portmann B., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
15. Ballot E., Homberg J.C., Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 autoimmune hepatitis. J Hepatol 2000, 33:208-215.
16. Czaja A.J., Shums Z., Norman G.L. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002, 35:475-483.
17. Torres-Collado A.X., Czaja A.J., Gelpi C. Anti-t-RNP(ser)sec/SLA/LP auto-antibodies. Comparative study using in-house Elisa with a recombinant 48.8kDa protein, immunoblot, and analysis of immuno-precipitated RNAs. Liver Int 2005, 25:410-419.
18. Vitozzi S., Djilali-Saiah I., Lapierre P., Alvarez F. Anti-soluble liver antigen/liver pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 2002, 35:485-492.
19. Vitozzi S., Lapierre P., Djilali-saiah I., Marceau G., Beland K., Alvarez F. Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection. Autoimmunity 2004, 37:217-222.
20. Eyraud V., Chazouillères O., Ballot E., Corpechot C., Poupon R., Johanet C. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 2009, 29:857-864.
21. Czaja A.J., Shums Z., Norman G.L. Non-standard antibodies as pronostic markers in autoimmune hepatitis. Autoimmunity 2004, 37:195-201.
22. Duclos-Vallée J.C., Sebagh M., Rifai K., Johanet C., Ballot E., Guettier C., et al. A 10-year follow-up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003, 52:893-897.
23. Baeres M., Herkel J., Czaja A.J., Kanzler S., Cancado E.L.R., Porta G., et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence and clinical characteristics. Gut 2002, 51:259-264.
24. Czaja A.J., Donaldson P.T., Lohse A.W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002, 97:413-419.
25. Vergani D., Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008, 14:3306-3312.